3/19/2010

Results of a large trial of Alzheimer's disease drug bapineuzumab might not be available until 2012 because maker Johnson & Johnson is still enrolling patients. The findings are highly anticipated by investors, analysts, physicians and patients waiting for progress in Alzheimer's treatment.

Related Summaries